BiotechTube

PF-07220060 + Midazolam

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung

Trial Timeline

Sep 23, 2020 → Nov 23, 2027

NCT ID
NCT04557449

About PF-07220060 + Midazolam

PF-07220060 + Midazolam is a phase 2 stage product being developed by Pfizer for Liposarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04557449. Target conditions include Liposarcoma, Prostate Cancer, Breast Neoplasms.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04557449Phase 2Active

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
efatutazoneDaiichi SankyoPhase 2
35
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
35
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
Sunitinib Malate (SU011248)PfizerPhase 2
35
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
11